492 Development of a tri-specific antibody targeting PD-1/CTLA-4/TIGIT

492 Development of a tri-specific antibody targeting PD-1/CTLA-4/TIGIT

Bibliographic Details
Main Authors:	Fei Peng, Qinglin Du, Tiantian Zhou, Xueyan Yang, Shuhua Han, Xueqin Li
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2023-11-01
Series:	Journal for ImmunoTherapy of Cancer

Similar Items

491 Generation of an innovative bispecific antibody targeting CCR8/CTLA4
by: Fei Peng, et al.
Published: (2023-11-01)

PD1, CTLA4 and TIGIT Expression on T and NK Cells in Granulomatous Diseases: Sarcoidosis and ANCA-Associated Vasculitis
by: Miriana d’Alessandro, et al.
Published: (2022-12-01)

Development of a bispecific antibody targeting PD-L1 and TIGIT with optimal cytotoxicity
by: Zhenwei Zhong, et al.
Published: (2022-10-01)

INFLUENCE OF ANTIBODIES AGAINST CTLA-4 AND PD-1 UPON QUANTITIES OF THEIR TARGET RECEPTORS
by: I. O. Chikileva, et al.
Published: (2019-01-01)

Molecular Interactions of Antibody Drugs Targeting PD-1, PD-L1, and CTLA-4 in Immuno-Oncology
by: Hyun Tae Lee, et al.
Published: (2019-03-01)

PD‐L1/TIGIT bispecific antibody showed survival advantage in animal model
by: Songlin Mu, et al.
Published: (2022-05-01)

Circulating TIGIT±PD1+TPH, TIGIT ± PD1+TFH cells are elevated and their predicting role in systemic lupus erythematosus
by: Qing Luo, et al.
Published: (2024-03-01)

Cadonilimab, a tetravalent PD-1/CTLA-4 bispecific antibody with trans-binding and enhanced target binding avidity
by: Xinghua Pang, et al.
Published: (2023-12-01)

289 Cadonilimab, an anti-PD1/CTLA4 bi-specific antibody with Fc effector null backbone
by: Na Chen, et al.
Published: (2021-11-01)

High co-expression of immune checkpoint receptors PD-1, CTLA-4, LAG-3, TIM-3, and TIGIT on tumor-infiltrating lymphocytes in early-stage breast cancer
by: Baran Mollavelioglu, et al.
Published: (2022-10-01)

A reporter gene assay for determining the biological activity of therapeutic antibodies targeting TIGIT
by: Zhihao Fu, et al.
Published: (2021-12-01)

790 DSP502 — A novel approach for targeting TIGIT and PD1 pathways for cancer immunotherapy
by: Shirley Greenwald, et al.
Published: (2021-11-01)

Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4
by: Shuang Qin, et al.
Published: (2019-11-01)

Tissue-Specific Expression of TIGIT, PD-1, TIM-3, and CD39 by γδ T Cells in Ovarian Cancer
by: Pauline Weimer, et al.
Published: (2022-03-01)

The landscape of TIGIT target and clinical application in diseases
by: Shu Rui, et al.
Published: (2022-09-01)

Co-inhibition of TIGIT and PD-1/PD-L1 in Cancer Immunotherapy: Mechanisms and Clinical Trials
by: Xianjing Chu, et al.
Published: (2023-06-01)

A Systematic Review and Meta-Analysis on the Significance of TIGIT in Solid Cancers: Dual TIGIT/PD-1 Blockade to Overcome Immune-Resistance in Solid Cancers
by: Negar Hosseinkhani, et al.
Published: (2021-09-01)

Targeting TIGIT for cancer immunotherapy: recent advances and future directions
by: Peng Zhang, et al.
Published: (2024-01-01)

4.492 Daylighting, Fall 2004
by: Andersen, Marilyne
Published: (2004)

Correction: Co-inhibition of TIGIT and PD-1/PD-L1 in Cancer Immunotherapy: Mechanisms and Clinical Trials
by: Xianjing Chu, et al.
Published: (2023-06-01)

Revolutionization in Cancer Therapeutics via Targeting Major Immune Checkpoints PD-1, PD-L1 and CTLA-4
by: Pratibha Pandey, et al.
Published: (2022-03-01)

Targeting TIGIT for Immunotherapy of Cancer: Update on Clinical Development
by: Anand Rotte, et al.
Published: (2021-09-01)

TIGIT as a Promising Therapeutic Target in Autoimmune Diseases
by: Chenran Yue, et al.
Published: (2022-06-01)

Addition of anti-TIM3 or anti-TIGIT Antibodies to anti-PD1 Blockade Augments Human T cell Adoptive Cell Transfer
by: Marina Martinez, et al.
Published: (2021-01-01)

DNA methylation and repressive H3K9 and H3K27 trimethylation in the promoter regions of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, and PD-L1 genes in human primary breast cancer
by: Varun Sasidharan Nair, et al.
Published: (2018-06-01)

TIGIT acts as an immune checkpoint upon inhibition of PD1 signaling in autoimmune diabetes
by: Prerak Trivedi, et al.
Published: (2024-03-01)

TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM
by: Alice L. Hung, et al.
Published: (2018-08-01)

Biophysical characterization of PVR family interactions and therapeutic antibody recognition to TIGIT
by: SJ J. Diong, et al.
Published: (2023-12-01)

Generating Anti-TIGIT and CD155 Monoclonal Antibodies for Tumor Immunotherapy
by: Yu-Hang Duan, et al.
Published: (2022-09-01)

Bispecific antibodies targeting CTLA-4: game-changer troopers in cancer immunotherapy
by: Pooya Farhangnia, et al.
Published: (2023-06-01)

Infusion-Related Reactions Induced by Cadonilimab (PD-1/CTLA-4 Bispecific Antibody): Seven Case Reports
by: Weiting Liang, et al.
Published: (2024-02-01)

The Dual Blockade of the TIGIT and PD-1/PD-L1 Pathway as a New Hope for Ovarian Cancer Patients
by: Anna Pawłowska, et al.
Published: (2022-11-01)

Immune checkpoint expression patterns on T cell subsets in light-chain amyloidosis: VISTA, PD-1, and TIGIT as potential therapeutic targets
by: Jinghua Wang, et al.
Published: (2024-01-01)

MicroRNAs as regulators of immune checkpoints in cancer immunotherapy: targeting PD-1/PD-L1 and CTLA-4 pathways
by: Arefeh Zabeti Touchaei, et al.
Published: (2024-03-01)

Development of a mechanism of action-reflective, dual target cell-based reporter bioassay for a bispecific monoclonal antibody targeting human CTLA-4 and PD-1
by: Weimin Chen, et al.
Published: (2021-01-01)

Immune Checkpoint Inhibitors: Ctla-4 and Pd-1/Pd-l1 in Immunotherapy
by: Kübra KAHVECİ, et al.
Published: (2019-12-01)

PVR/TIGIT and PD-L1/PD-1 expression predicts survival and enlightens combined immunotherapy in lung squamous cell carcinoma
by: Zhenlin Yang, et al.
Published: (2022-10-01)

Knockout of the inhibitory receptor TIGIT enhances the antitumor response of ex vivo expanded NK cells and prevents fratricide with therapeutic Fc-active TIGIT antibodies
by: Dean A Lee, et al.
Published: (2023-12-01)

Phase I trial of KN046, a novel bispecific antibody targeting PD-L1 and CTLA-4 in patients with advanced solid tumors
by: Yang Zhang, et al.
Published: (2023-06-01)

Inborn Errors of Immunity and Their Phenocopies: CTLA4 and PD-1
by: Yuwei Hao, et al.
Published: (2022-01-01)